clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT00051012 |
P6099 | clinical trial phase | phase IV clinical trial | Q42825046 |
P17 | country | Canada | Q16 |
United States of America | Q30 | ||
Poland | Q36 | ||
Switzerland | Q39 | ||
Australia | Q408 | ||
Germany | Q183 | ||
Austria | Q40 | ||
United Kingdom | Q145 | ||
P582 | end time | 2006-10-01 | |
P1050 | medical condition | lymphoma | Q208414 |
mycosis fungoides | Q1891209 | ||
P2899 | minimum age | 18 | |
P1132 | number of participants | 86 | |
P6153 | research site | Jewish General Hospital | Q3145341 |
Southampton General Hospital | Q7569131 | ||
University Hospital Muenster | Q1748138 | ||
P580 | start time | 1995-09-01 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | A Multicenter Open-Label Study to Evaluate the Safety and Efficacy of DAB389IL-2 in Cutaneous T-Cell Lymphoma (CTCL) Patients Following Protocol 93-04-10, Protocol 93-04-11, or Protocol 92-04-01 or Who Meet the Requirements for Protocol 93-04-11 Except Have Biopsy-Documented CTCL That Does Not Express CD25 |